Powered By
Researchers estimate that between 70 percent and 80 percent of people treated for ovarian cancer have a recurrence, meaning the cancer returns after initial treatment. Recurrences are also called relapses.
Ovarian cancer is a type of gynecologic cancer that includes cancers of the ovary, fallopian tube, or peritoneum (the lining of the abdominal cavity). The condition is often difficult to detect early because it may not cause symptoms at first. As a result, about 80 percent of cases aren’t diagnosed until the disease has already reached a more advanced stage.
While relapse is common, not everyone will experience one. With regular monitoring, such as blood tests and imaging, relapses can often be caught early — when they may be more manageable and responsive to treatment. Ongoing care and communication with your healthcare team are key to staying on top of your health.
If your ovarian cancer was diagnosed at an earlier stage, the chances of it returning are generally lower. The likelihood of recurrence can vary based on the stage at diagnosis:
Keep in mind that these numbers are averages drawn from large groups of people. They are not predictions for any one person. Each individual’s experience with ovarian cancer is unique.
Progression-free survival refers to the amount of time after treatment during which the cancer does not grow or come back. It's an important measure doctors use to evaluate how well a treatment is working, though it's not the same as a personal prognosis.
For people with advanced ovarian cancer, the median PFS (meaning half of people go longer, half go shorter) has historically ranged from about 16 to 21 months after initial treatment. This is particularly true among people who’ve been treated with standard chemotherapy like carboplatin and paclitaxel. These numbers come from earlier clinical trials, and newer therapies may help extend PFS in some people.
The timing of recurrence varies widely. Some people may experience recurrence sooner, while others go much longer without a return of disease.
If your ovarian cancer comes back, your doctor may estimate your prognosis (outlook). Certain factors may indicate a better prognosis following a recurrence of ovarian cancer. Some of these factors include:
Overall survival refers to the length of time people with ovarian cancer are still alive after diagnosis. Researchers often use the term “five-year relative survival rate,” which compares how likely people with a certain type and stage of cancer are to live at least five years after diagnosis, compared to those without cancer.
Survival rates can vary widely depending on the type and stage of ovarian cancer at diagnosis. Following are the most recent five-year relative survival rates for different types of ovarian cancer, based on how far the cancer had spread when it was first diagnosed.
For invasive epithelial ovarian cancer (the most common type):
For ovarian stromal tumors:
For germ cell tumors of the ovary:
Recurrent ovarian cancer has worse overall survival rates. The median time people live after having an ovarian cancer relapse is two years. However, these statistics don’t predict what your outcome will be. Your doctor can help you get a better understanding of your outlook based on your characteristics.
Recurrent ovarian cancer may cause the same symptoms as the original cancer, or these symptoms may be different. The most common symptoms that often cause the greatest amount of trouble for people living with ovarian cancer are:
Other symptoms are frequently found as well. These can include nausea, bowel changes, and bloating.
Once you’ve been treated for ovarian cancer, you’ll probably need regular follow-up appointments with your doctor to check for signs that the cancer has recurred. Your doctor will likely give you a physical exam and ask you questions to identify whether you’re having any advanced ovarian cancer symptoms. They may also have you undergo blood tests or imaging tests to identify possible cancer signs.
The first systemic treatment you receive after you’re initially diagnosed with ovarian cancer is called first-line therapy. For ovarian cancer, this often includes chemotherapy.
First-line chemotherapy usually consists of a drug that contains platinum, such as cisplatin and carboplatin, and possibly a type of chemotherapy drug called a taxane, such as paclitaxel. The goal of first-line therapy is to try to eliminate as many cancer cells from your body as possible, or it may be to slow the growth of an advanced tumor.
If first-line treatments have been successful and your cancer has shrunk, your doctor will probably recommend that you start maintenance therapy. The goal of these treatments is to keep your cancer under control and prevent your cancer from progressing.
There are a few types of maintenance therapy used for ovarian cancer. One of these is bevacizumab. This drug stops tumors from using blood vessels to feed themselves and grow.
Another type of maintenance therapy is a category of drugs called poly (ADP-ribose) polymerase, or PARP, inhibitors. PARP inhibitors include olaparib (Lynparza), niraparib (Zejula), and rucaparib (Rubraca). PARP inhibitors make it harder for cancer cells to repair DNA damage, leaving them more vulnerable. These drugs are especially effective in treating cancers with mutations in the BRCA gene.
If your ovarian cancer comes back, the treatments you receive may be the same as they were the first time around, or they may be different. The treatment you receive may depend on factors like:
A person’s treatment goals may change over time. For recurrent disease, the goals are often to:
Chemotherapy is often used to treat ovarian cancer that has relapsed. If your cancer took more than six months to come back, it’s called platinum-sensitive. This means that the platinum-based drugs used the first time around, like carboplatin, will probably work again.
If cancer returned within six months after the first treatment, it’s called platinum-resistant or refractory. If you have platinum-resistant disease, you’ll probably receive a different chemotherapy regimen that includes other drugs like paclitaxel, pegylated liposomal doxorubicin, gemcitabine, and topotecan.
Chemotherapy isn’t the right choice for everyone. These drugs may do more harm than good for people who aren’t expected to benefit from them.
If you have recurrent ovarian cancer, you may have debulking surgery to remove the cancer. Whether or not you have surgery depends on:
Targeted therapy drugs can seek out and kill cancer cells. Some of these medications are also used in maintenance therapy and may include:
Your oncology team may also recommend that you try an antibody-drug conjugate. This class of drugs identifies, targets, and destroys specific ovarian cancer cells. One drug in this category is called mirvetuximab soravtansine-gynx (Elahere). It was approved in 2024 to treat platinum-resistant epithelial ovarian cancer, peritoneal cancer, or fallopian tube cancer.
A newer targeted therapy called Avmapki Fakzynja Co-Pack, a combination of avutometinib and defactinib, was approved in 2025. It’s approved for adults with recurrent KRAS-mutated, low-grade serous ovarian cancer (LGSOC). This is the first targeted treatment specifically for KRAS-mutated LGSOC, which is a rare and hard-to-treat form of ovarian cancer.
You may receive targeted therapy during treatment the first time around, or you may receive it later if ovarian cancer recurs.
You may receive radiotherapy treatments to make tumors smaller. Radiotherapy uses high-energy beams to kill cancer cells. It may also help reduce symptoms or kill cancer that’s spread to other places in the body.
No matter the stage of your ovarian cancer, you can also consider palliative care. Palliative, or supportive, care is not the same as hospice care and doesn’t necessarily mean that you’re at the end of your life. It focuses on reducing cancer symptoms, such as pain, and it can be used along with any other treatments you may want to pursue. It can help people have a better quality of life and may even lead to better outcomes.
Fighting cancer is hard enough the first time around, and it can be even more challenging the next. Many people with recurrent ovarian cancer have a hard time managing tests, treatments, and an uncertain future. It’s common to feel depressed, sad, angry, or scared.
Ask your oncologist about support services available through your hospital or cancer care center, or for referrals. Social workers, therapists, and chaplains can help you manage the emotions and practical challenges of recurrent cancer. They can also help you cope with feelings of stress or anxiety that may result while living with advanced ovarian cancer.
On MyOvarianCancerTeam, people share their experiences with ovarian cancer, get advice, and find support from others who understand.
Has your ovarian cancer recurred? Let others know in the comments below.
Get updates directly to your inbox.
How Many Times Has Your Cancer Come Back?
Continue with Facebook
Continue with your email
Become a member to get even more
Join
A MyOvarianCancerTeam Member
I was diagnosed January 2nd with 4th recurrence. I am going to beat the damn cancer again. I have a lot of living left to do!
We'd love to hear from you! Please share your name and email to post and read comments.
You'll also get the latest articles directly to your inbox.